Skip to content
OpenCapital
Get started

Design Therapeutics, Inc. DSGN Q1 2025 earnings

Reported May 7, 2025 · Before market open

Revenue-
EPS-$0.31Miss by $0.03
EPS estimate-$0.28

Next report

Aug 6, 2026 (In 1 week)
EPS estimate-$0.36

Financials

Q1 2025

Income statement

See full
Revenue-—
Operating income-$20.4M-41.8%
Net income-$17.7M-59.5%
EPS (diluted)-$0.31-55.0%

Balance sheet

See full
Cash & equivalents$13.7M-53.5%
Total debt$2.1M-25.6%
Total equity$227.9M-15.4%
Total assets$237.5M-14.8%

Cash flow

See full
Operating cash flow-$16.8M-35.0%
CapEx$72.0K-63.1%
Free cash flow-$16.9M-33.5%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$219.1M-2.9%
Enterprise value$207.58M+4.3%

Returns & leverage

See full
Return on equity-22.6%+3.1pp
Debt / equity0×0.0×
Current ratio28.4×-10.2×

Versus estimates

Diluted EPS

Q1 2026-$0.29Beat by $0.07Q4 2025-$0.27Beat by $0.11Q3 2025-$0.30Beat by $0.04Q2 2025-$0.34Miss by $0.02
Q1 2025-$0.31Miss by $0.03
Q4 2024-$0.24Beat by $0.04

Ask the moment Design Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Design Therapeutics, Inc. report Q1 2025 earnings?
Design Therapeutics, Inc. (DSGN) reported Q1 2025 earnings on May 7, 2025 before market open.
What were Design Therapeutics, Inc.'s Q1 2025 revenue and EPS?
Design Therapeutics, Inc. reported revenue of - and eps of $-0.31 for Q1 2025.
Did Design Therapeutics, Inc. beat estimates in Q1 2025?
EPS missed the consensus estimate of $-0.28 by $0.03.
How did Design Therapeutics, Inc.'s Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 55.0% from $-0.20.
Where can I find Design Therapeutics, Inc.'s Q1 2025 SEC filings?
You can read the 10-Q periodic report (0000950170-25-065643) directly on SEC EDGAR. The filing index links above go to sec.gov.